At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMRX Immuneering Corp
Post-Market Trading 11-05 19:06:39 EST
1.96
+0.10
+5.38%
盘后1.95
-0.01-0.47%
18:21 EST
High1.98
Low1.86
Vol183.70K
Open1.86
D1 Closing1.86
Amplitude6.45%
Mkt Cap58.12M
Tradable Cap37.46M
Total Shares29.65M
T/O356.43K
T/O Rate0.96%
Tradable Shares19.11M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.